Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Iovance Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Iovance Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vogt Frederick G | Interim CEO & General Counsel | 595,447 | Sep 10, 2026 | 8 |
| Bilinsky Igor | Chief Operating Officer | 142,074 | Sep 10, 2026 | 8 |
| Puri Raj K. | Chief Regulatory Officer | 256,364 | Sep 10, 2026 | 9 |
| Kirby Daniel Gordon | Chief Commercial Officer | 154,511 | Aug 12, 2026 | 5 |
| Roche Corleen M. | Chief Financial Officer | 28,757 | Aug 10, 2026 | 2 |
| Weiser Michael | Director | 112,632 | Jun 18, 2026 | 1 |
| Maynard Ryan D | Director | 7,500 | Jun 18, 2026 | 1 |
| Countouriotis Athena | Director | – | Jun 18, 2026 | 1 |
| Dukes Iain D. | Director | 54,000 | Jun 18, 2026 | 1 |
| Graf Finckenstein Friedrich | Chief Medical Officer | 140,111 | Jun 9, 2026 | 6 |
| Yarno Wendy L | Director | – | Jun 17, 2025 | 0 |
| Bellemin Jean-Marc | Chief Financial Officer | 60,529 | Jun 4, 2025 | 0 |
| McPeak Merrill A | Director | 320,150 | Mar 5, 2024 | 0 |
| Rothbaum Wayne P. | Director | 28,067,333Indirect | Mar 5, 2024 | 0 |
| Dixon Wendy L | Director | – | Jun 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Kirby Daniel GordonChief Commercial Officer | PPurchase | +30.0K | $1.84 | +$55.2K | New position30.0K after | |
| May 27, 2025 (view filing) | May 23 | 4 days | Puri Raj K.Chief Regulatory Officer | PPurchase | +5.60K | $1.74 | +$9.74K | +2.8%206.9K after | |
| May 16, 2025 (view filing) | May 14 | 2 days | Vogt Frederick GInterim CEO & General Counsel | PPurchase | +25.0K | $1.69 | +$42.3K | +7.2%374.6K after | |
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | Maynard Ryan DDirector | SSale | −50.0K | $10.06 | −$503.0K | −87.0%7.50K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | McPeak Merrill ADirector | PPurchase | +250.0K | $9.15 | +$2.29M | +356.4%320.1K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | Dukes Iain D.Director | PPurchase | +32.0K | $9.15 | +$292.8K | +145.5%54.0K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | Rothbaum Wayne P.Director | PPurchase | +5.00M | $9.15 | +$45.8M | +21.7%28.1M after | |
| Sep 19, 2023 (view filing) | Sep 18 | 1 day | McPeak Merrill ADirector | PPurchase | +10.0K | $5.56 | +$55.6K | +4.2%248.6K after | |
| Sep 15, 2023 (view filing) | Sep 15 | Same day | Rothbaum Wayne P.Director | PPurchase | +5.00M | $5.30 | +$26.5M | +27.7%23.1M after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | McPeak Merrill ADirector | PPurchase | +10.0K | $6.15 | +$61.5K | +16.6%70.2K after | |
| Dec 2, 2022 (view filing) | Dec 2 | Same day | Rothbaum Wayne P.Director | PPurchase | +10.0M | $6.50 | +$65.0M | +124.0%18.1M after | |
| Nov 30, 2022 (view filing) | Nov 29 | 1 day | McPeak Merrill ADirector | PPurchase | +10.0K | $6.31 | +$63.1K | +4.4%238.6K after | |
| Nov 28, 2022 (view filing) | Nov 28 | Same day | Vogt Frederick GInterim CEO & General Counsel | PPurchase | +1.00K | $5.98 | +$5.98K | +100.0%2.00K after | |
| Nov 28, 2022 (view filing) | Nov 28 | Same day | McPeak Merrill ADirector | PPurchase | +10.0K | $6.18 | +$61.8K | +4.6%228.6K after | |
| Nov 28, 2022 (view filing) | Nov 23 | 5 days | Dukes Iain D.Director | PPurchase | +10.0K | $6.10 | +$61.0K | +83.3%22.0K after | |
| Jun 2, 2022 (view filing) | May 31 | 2 days | McPeak Merrill ADirector | PPurchase | +10.0K | $6.84 | +$68.4K | +98.5%20.1K after | |
| Jun 2, 2022 (view filing) | May 31 | 2 days | McPeak Merrill ADirector | PPurchase | +10.0K | $6.80 | +$68.0K | +4.8%218.6K after | |
| Jun 2, 2022 (view filing) | May 31 | 2 days | Maynard Ryan DDirector | PPurchase | +7.50K | $6.75 | +$50.6K | New position7.50K after | |
| Jun 2, 2022 (view filing) | May 31 | 2 days | Weiser MichaelDirector | PPurchase | +10.0K | $6.80 | +$68.0K | +9.7%112.6K after | 2 lots |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Vogt Frederick GInterim CEO & General Counsel | PPurchase | +1.00K | $6.44 | +$6.44K | New position1.00K after | |
| Jun 2, 2022 (view filing) | May 31-Jun 1 | 2 days | Rothbaum Wayne P.Director | PPurchase | +1.00M | $6.60 | +$6.60M | +14.1%8.07M after | 2 lots |